NANOBIOTIX TO HOST VIRTUAL KOL EVENT DISCUSSING POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 IN IMMUNOTHERAPY ON JUNE 11, 2021 Paris, France; Cambridge, Massachusetts (USA)

NANOBIOTIX TO HOST VIRTUAL KOL EVENT DISCUSSING POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 IN IMMUNOTHERAPY ON JUNE 11, 2021

Paris, France; Cambridge, Massachusetts (USA); June 7, 2021 - NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the "Company''), a late-clinical stage biotechnology company pioneering

physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL event for analysts, investors, and the scientific community on Friday, June 11, 2021 at 8AM ET / 2PM CET. The event

will feature several key opinion leaders, including current study investigators.

The Nanobiotix KOL event will provide an in-depth review of the immunotherapy data presented at the 2021 Annual Meeting of American Society for Clinical

Oncology (ASCO) along with clinical perspectives on the implications of potential first-in-class radioenhancer NBTXR3 across the oncology landscape.

Registration for the event is now open on the events section of the Company's website. A live webcast of the discussion and an archived

recording will be available on the events section as well.

Nanobiotix Virtual KOL Event Program

Can NBTXR3 Turn Anti-PD-1 Non-responders into Responders and Deepen Response in Na ve Patients?

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by

people committed to making a difference for humanity. The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been

listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders

of the central nervous system. The Company's resources are primarily devoted to the development of its lead product candidate-NBTXR3-which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for

the treatment of patients with soft tissue sarcoma under the brand name Hensify .

This press release contains certain "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation

Reform Act of 1995. Forward-looking statements may be identified by words such as "at this time," "anticipate," "believe," "expect," "intend," "on track," "plan," "scheduled," and "will," or the negative of these and similar expressions. These

forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management, include statements about the timing and progress of clinical trials, the timing of our

presentation of data, the results of our preclinical and clinical studies and their potential implications, the development and commercialization of NBTXR3, and the execution of the Company's development and

commercialization strategy. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However, these forward-looking statements are subject to

numerous risks and uncertainties, including with respect to the risk that subsequent studies and ongoing or future clinical trials may not generate favorable data notwithstanding positive preclinical or early clinical result and the risks

associated with the evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to it. Furthermore, many other important factors, including those described in Annual Report

on Form 20-F filed with the U.S. Securities and Exchange Commission on April 7, 2021 under "Item 3.D. Risk Factors" and those set forth in the universal registration document of Nanobiotix filed with the French Financial Markets Authority (Autorit

des march s financiers) under number D.21-0272 on April 7, 2021 (a copy of which is available on www.nanobiotix.com), as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our

actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to

update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.